A Test That Has Caused More Debate Than Almost Any Other
Prostate-specific antigen (PSA) testing was introduced as a prostate cancer screening tool in the late 1980s and led to dramatic increases in prostate cancer diagnosis. It also led to overdiagnosis and overtreatment of cancers that would never have caused harm.
After two decades of swinging recommendations, current guidelines have settled into a more nuanced position: shared decision-making between patient and clinician, with screening being a personal choice informed by individual risk factors and values rather than a universal recommendation.
At Zimmer Medical Group, we have this conversation with every man approaching the appropriate age range and tailor the discussion to each patient's situation.
What PSA Actually Measures
PSA is a protein produced by both normal and cancerous prostate cells. The blood test simply measures total PSA in nanograms per milliliter (ng/mL). Higher levels suggest more prostate activity — but elevated PSA can come from:
- Prostate cancer
- BPH (benign enlargement) — the most common cause of mild elevation
- Prostatitis
- Recent ejaculation (within 24 hours)
- Recent vigorous bicycling
- Recent prostate manipulation (DRE, catheterization)
- Urinary tract infection
- Some medications affect PSA
The test is sensitive but not specific — many elevated PSAs are not cancer.
Why the Recommendations Have Changed
For years, PSA screening was nearly universal. Studies eventually showed:
- Many cancers detected by PSA screening were indolent (low-grade, slow-growing)
- Treatment of these indolent cancers caused significant side effects (incontinence, erectile dysfunction)
- The mortality benefit of screening was real but modest
The pendulum swung against screening, then settled into the current shared decision-making approach as we got better at distinguishing aggressive from indolent cancer through:
- More refined risk assessment
- Active surveillance for low-risk cancers
- MRI-targeted biopsy reducing unnecessary biopsies
- Better understanding of who benefits most from screening
Current Guidelines
USPSTF Recommendations
The US Preventive Services Task Force recommends:
- Men ages 55–69: shared decision-making — Grade C (selectively offer)
- Men 70 and older: screening not recommended — Grade D
- Men under 55: insufficient evidence for general population
Other Guidelines
- American Cancer Society: discussion starting at age 50 for average risk; age 45 for higher risk; age 40 for highest risk
- American Urological Association: routine screening between 55 and 69; consider earlier for high-risk men
- National Comprehensive Cancer Network: discussion starting at age 45–50
The differences reflect ongoing evolution as more data emerges.
Who Benefits Most From Screening
Several groups have higher prostate cancer risk and may benefit more:
- African American men — significantly higher incidence and mortality
- Family history — especially first-degree relative diagnosed before age 65
- BRCA1 or BRCA2 mutation carriers — see our BRCA testing guide
- Lynch syndrome carriers
- Multiple affected family members
For these men, earlier and more careful screening discussions are appropriate.
Who May Benefit Less
- Men with limited life expectancy (typically less than 10 years from comorbidities)
- Men over 70–75 in average health
- Men who would not pursue treatment if cancer were found
How to Have the Conversation
A good PSA discussion covers:
Potential Benefits
- Detection of aggressive cancer when treatment can cure it
- Modest reduction in prostate cancer mortality (numbers needed to screen are substantial)
- Peace of mind (for some patients)
Potential Harms
- False positive PSAs leading to anxiety and unnecessary procedures
- Biopsy risks: bleeding, infection, discomfort
- Overdiagnosis of cancers that would not have caused harm
- Treatment-related side effects: incontinence, erectile dysfunction, bowel changes
- Anxiety from a "cancer" label even for indolent disease
Personal Values
- How would you feel about active surveillance vs. treatment for low-risk cancer?
- How would significant treatment side effects affect your quality of life?
- What is your tolerance for uncertainty and follow-up testing?
- What is your family history?
- What is your overall health and life expectancy?
Interpreting Your PSA
There is no single "normal" cutoff. Historical thresholds:
- < 4 ng/mL: historically normal (but cancer can occur)
- 4–10 ng/mL: "gray zone" — significant overlap with BPH
- > 10 ng/mL: higher cancer risk
More refined approaches consider:
- PSA velocity — rate of change over time (rapid rises more concerning)
- PSA density — PSA divided by prostate volume
- Free PSA percentage — lower percentage suggests higher cancer risk
- Age-specific reference ranges
- PSA-based markers like 4Kscore, PHI (Prostate Health Index)
For elevated PSA, repeat testing after a few weeks (avoiding triggers) is often the first step before further workup.
What Happens After an Elevated PSA
Modern workup increasingly involves:
Step 1: Confirm
- Repeat PSA in a few weeks
- Avoid recent ejaculation, vigorous cycling, recent prostate manipulation
- Address active UTI or prostatitis if present
Step 2: Risk Refinement
- Free PSA, PSA density, or other adjuncts
- Sometimes urinary biomarker tests (PCA3, ExoDx)
Step 3: MRI
Multiparametric MRI of the prostate has transformed prostate cancer evaluation. It can:
- Identify suspicious lesions
- Reduce unnecessary biopsies
- Guide biopsies to abnormal areas
- Sometimes reassure patients with negative MRIs
PI-RADS scoring quantifies suspicion: PI-RADS 1–2 (low), 3 (equivocal), 4–5 (likely significant cancer).
Step 4: Biopsy When Indicated
- Transrectal or transperineal approach
- MRI-targeted (for visible lesions) plus systematic sampling
- Risk of bleeding, infection, discomfort
- Definitive for diagnosis when needed
Active Surveillance
A major treatment advance: many low-risk prostate cancers can be safely monitored rather than immediately treated. Active surveillance involves:
- Periodic PSA testing
- Periodic MRI
- Periodic biopsies
- Treatment intervention if disease progresses
This approach maintains the option of cure while avoiding treatment side effects in patients whose cancers would never have caused harm. It is now standard care for low-risk disease in appropriately selected patients.
Stopping Screening
For most men:
- Stop screening when life expectancy is less than 10 years from age and comorbidities
- This typically means most men over 70–75 in average health stop screening
- Healthier older men may continue selectively
- Patients diagnosed with low-risk cancer who would prefer active surveillance often warrant continued PSA monitoring
What I Tell Patients
A practical framework for the conversation:
- Most men should have a PSA discussion between ages 50 and 70
- High-risk men should start the discussion earlier (age 40–45)
- Most men over 70–75 in average health should stop screening
- An elevated PSA is not a cancer diagnosis
- Modern workup uses MRI before reflexive biopsy in many cases
- If cancer is found, treatment is increasingly individualized and active surveillance is often appropriate
- The decision is yours; my role is to give you the information to make it
When to See Your Doctor
- Approaching age 50 (40–45 if high-risk)
- Family history of prostate cancer
- New urinary symptoms
- Previous PSA results to discuss
- Considering whether to continue or stop screening
- Recently diagnosed and considering treatment options
The American Cancer Society and American Urological Association provide additional patient resources on PSA screening decisions.
Approaching age 50 or have questions about prostate cancer screening? Contact Zimmer Medical Group for a thoughtful conversation about whether and how to screen, based on your individual risk and values.
